Avrion Therapeutics

Avrion Therapeutics was founded in 2020 based on more than 10 years of research at the Brain Mind Institute at EPFL, the Swiss Federal Institute of Technology Lausanne, led by the groups of Dr. Bernard Schneider and Prof. Brian McCabe. Central to this research was the discovery that protecting synapses, the connections that enable communication among neurons in the brain and between the brain and the body, is essential to combating neurodegenerative disease.

Avrion is focused on preserving motor synapses in Amyotrophic Lateral Sclerosis (ALS). Also known as Motor Neuron Disease (MND), Lou Gehrig’s disease or "maladie de Charcot", ALS is a progressive and ultimately fatal neurodegenerative disorder of the motor system affecting approximately 300,000 people worldwide. Synapse loss is an early and critical event in the progressive deterioration of motor function across all forms of ALS. Preserving vulnerable synapses offers a new strategy for the treatment of ALS.